Marguerite Beiser

Ms. Marguerite Beiser

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2006 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JHJeff C. Huffman
Jeff C. Huffman
FSFelicia A. Smith
Felicia A. Smith
MBMark Blais
Mark Blais
MBMarguerite Beiser
Marguerite Beiser
JJJames Januzzi
James Januzzi
GFGregory Fricchione
Gregory Fricchione

1 October 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MBMarguerite Beiser
Marguerite Beiser
KSKamala Smith
Kamala Smith
MIMolly Ingemi
Molly Ingemi
EMEmma Mulligan
Emma Mulligan
TBTravis P. Baggett
Travis P. Baggett

1 June 2017 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
JBJoshua A. Barocas
Joshua A. Barocas
MBMarguerite Beiser
Marguerite Beiser
CLCasey León
Casey León
JGJessie M. Gaeta
Jessie M. Gaeta
JOJames J. O’cOnnell
James J. O’cOnnell
BLBenjamin P. Linas
Benjamin P. Linas
Approximately 44% of homeless adults are hepatitis C virus (HCV)-infected.1-5 Historically, homeless and marginally housed (HMH) adults have faced barriers to HCV treatment. New, interferon-free therapies have excellent cure rates and improved tolerability, reducing barriers for treatment.6 To our knowledge, no published studies have documented the treatment of HMH populations with these therapies. The Boston Health Care for the Homeless Program (BHCHP) began treating HMH adults with oral agents in 2014.

27 April 2006 in Heart
Verified
Journal Article
Closed access
JHJ C Huffman
J C Huffman
FSF A Smith
F A Smith
MBM A Blais
M A Blais
MBMarguerite Beiser
Marguerite Beiser
JJJ L Januzzi
J L Januzzi
GFG L Fricchione
G L Fricchione
Objective: To determine the ability of three questions from the Beck Depression Inventory II (BDI-II) to detect major depressive disorder (MDD) in a cohort of patients hospitalised for acute myocardial infarction (MI). Design: Prospective observational study. Setting: Coronary care unit and cardiac step-down unit of an urban academic medical centre. Patients: 131 post-MI patients within 72 h of symptom onset. Interventions: Patients were administered the BDI-II and participated in a structured diagnostic interview for MDD. Three individual BDI-II items (regarding sadness, loss of interest and loss of pleasure) were examined individually and in two-question combinations to determine their ability to screen for MDD. Main outcome measures: Sensitivity, specificity, negative and positive predictive values and proportion of patients with MDD correctly identified. Results: The individual items and two-question combinations had good sensitivity (76–94%), specificity (70–88%) and negative predictive values (97–99%). Item 1 (sadness) performed the best of the individual items (48% with a positive response to the item had MDD; 3% with a negative response had MDD; over 80% of patients with MDD were correctly identified). A combination of questions about sadness and loss of interest performed best among the two-question combinations (37% with positive response had MDD v 1% with a negative response; 94% of patients with MDD were identified). Conclusions: One to two questions regarding sadness and loss of interest serve as simple and effective screening tools for post-MI depression.

1 January 2017 in Journal Of Health Care For The Poor and Underserved
Verified
Journal Article
Closed access
PDF file
MBMarguerite Beiser
Marguerite Beiser
CLCasey Leon
Casey Leon
JGJessie M. Gaeta
Jessie M. Gaeta
The advent of tolerable, efficacious therapies for hepatitis C virus (HCV) creates an opportunity to provide HCV treatment for individuals experiencing homelessness. A federally-qualified community health center serving individuals experiencing homelessness in Boston conducted an anonymous needs assessment survey of a sample of HCV-infected patients in order to inform development of an HCV treatment program (N = 240). Primary care providers (PCPs) were identified as the chief source of HCV education. Main motivators to consider HCV treatment were identified as “taking care of your health” (73.5%) and “your provider says you should get treated” (53.6%). Interest and confidence to complete HCV treatment were high. The majority of respondents (51.4%) preferred to receive HCV treatment in the primary care setting. Preference for PCP-based treatment was significant compared to liver specialty-based treatment (30.8%, p < .0001). This is the first assessment of its kind describing the preferences of homeless individuals concerning hepatitis C treatment.

4 March 2023 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
MBMarguerite Beiser
Marguerite Beiser
LSLeah C Shaw
Leah C Shaw
SSSavanna K Shores
Savanna K Shores
JCJoanne M Carson
Joanne M Carson
BHBehzad Hajarizadeh
Behzad Hajarizadeh
Background: People experiencing homelessness are disproportionately affected by hepatitis C virus (HCV) infection compared with housed populations. Surveillance for HCV reinfection after successful treatment is a critical step in the care cascade, but limited data on reinfection are available among this highly marginalized group. This study assessed posttreatment reinfection risk in a real-world cohort of homeless-experienced individuals in Boston. Methods: Individuals receiving HCV direct-acting antiviral treatment through Boston Health Care for the Homeless Program during 2014–2020 with posttreatment follow-up assessment were included. Reinfection was identified based on recurrent HCV RNA at 12 weeks posttreatment with HCV genotype switch or any recurrent HCV RNA following sustain virologic response. Results: A total of 535 individuals were included (81% male, median age 49 years, 70% unstably housed or homeless at treatment initiation). Seventy-four HCV reinfections were detected, including 5 second reinfections. HCV reinfection rate was 12.0/100 person-years (95% confidence interval [CI]: 9.5–15.1) overall, 18.9/100 person-years (95% CI: 13.3–26.7) among individuals with unstable housing and 14.6/100 person-years (95% CI: 10.0–21.3) among those experiencing homelessness. In adjusted analysis, experiencing homelessness (vs stable housing, adjusted hazard ratio, 2.14; 95% CI: 1.09–4.20; P = .026) and drug use within 6 months before treatment (adjusted hazard ratio, 5.23; 95% CI: 2.25–12.13; P < .001) were associated with increased reinfection risk. Conclusions: We found high HCV reinfection rates in a homeless-experienced population, with increased risk among those homeless at treatment. Tailored strategies to address the individual and systems factors impacting marginalized populations are required to prevent HCV reinfection and to enhance engagement in posttreatment HCV care.